Evaluation of plasma angiotensinogen(AGT) and the effect of DRI on AGT and RAAS in hemodialysis patients

Evaluation of plasma angiotensinogen(AGT) and the effect of DRI on AGT and RAAS in hemodialysis patients - Evaluation of plasma AGT and effect of DRI in hemodiarysis patients.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006479

Enrollment

Registered

2011-10-05

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients Hypertension

Interventions

Aliskiren(150mg/day)8weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients 1. who have been under regular sessions for more than three months since the introduction of hemoddialysis. 2. with sBP>140mmHg or dBP>90mmHg at the beginning of the first hemodialysis session of the week.

Exclusion criteria

Exclusion criteria: 1.Pregnancy 2.Severe hepatic or gallbladder disease (GOT > 150 IU or GPT > 150 IU) 3.Hyper potassium(k > 5.5 mEq/L) 4.Malignant tumor 5.Allergy to Aliskiren 6.During administration of itraconazole or ciclosporin 7.Other inadequacies

Design outcomes

Primary

Measure	Time frame
Plasma AGT:0,2D,4D,7D,9D,11D,2,3,4,6,8W	—

Secondary

Measure	Time frame
1)BP:0,2D,4D,7D,9D,11D,2,3,4,6,8W 2)Plasma renin activity: 0,2D,4D,7D,9D,11D,2,3,4,6,8W Plasma renin concentration: 0,2D,4D,7D,9D,11D,2,3,4,6,8W 3)Plasma aldosterone:0,8W 4)proBNP:0,8W 5)Body Weight: 0,2D,4D,7D,9D,11D,2,3,4,6,8W 6)BUN, Cr:0,1,2,4,6,8W 7)Na, K, Cl, Ca, P:0,1,2,4,6,8W 8)CBC:0,1,2,4,6,8W	—

Countries

Japan

Contacts

Public ContactKumiko Kaifu

Kagawa University, Faculty of Medicine Department of Cardiorenal and Cerebrovascular Medicine

kumi-kai@med.kagawa-u.ac.jp087-891-2149

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026